The structural diversity of psychedelic drug actions revealed

Introduction

Gumpper and colleagues situate this work within a renewed interest in classical psychedelics as potential treatments for depression, addiction, anxiety, cluster headaches and other neuropsychiatric conditions. They note that although many psychedelics share agonism at the 5-HT2A serotonin receptor, the molecular basis for differences in hallucinogenicity, signalling bias (G-protein versus β-arrestin pathways), receptor selectivity and partial agonism remains poorly understood. Two competing molecular hypotheses motivating the field are summarised: hallucinations may arise from β-arrestin2 biased signalling at 5-HT2A, or alternatively a threshold of G-protein activation may determine hallucinogenic effects, with partial agonists producing non-hallucinogenic activity. The authors also mention circuit-level hypotheses linking therapeutic effects to rapid induction of neuroplasticity after single doses, as observed in some clinical trials of psilocybin. This study sets out to resolve ligand-specific molecular interactions by determining seven cryo-EM structures of the active, Gq-coupled 5-HT2A receptor bound to representative ligands from major chemotypes: 5-HT, psilocin, DMT (tryptamines), mescaline and phenethylamine-derived RS130-180 (phenethylamines), LSD and its non-hallucinogenic analogue 2-bromo-LSD (BOL, ergolines). By combining structural, mutational and functional data, the investigators aim to identify common and distinct receptor contact motifs that can explain biased signalling, selectivity, and partial agonism, and thereby inform rational design of novel chemotypes with therapeutic potential and fewer side effects.